Skip to main content
. 2017 Aug 3;8(46):81441–81454. doi: 10.18632/oncotarget.19888

Table 1. Demographic and baseline characteristics (N = 23).

Characteristic Number (percent)
Age (yr) Mean 62
Range 44-80
Sex Male 11 (48)
Female 12 (52)
Race White 20 (87)
Black or African American 3 (13)
ECOG performance status 0 5 (22)
1 13 (57)
2 5 (22)
Study disease at entry Disease progression during EP chemotherapy 9 (39)
Relapse ≤90 days from previous EP treatment 11 (48)
SD as best response after at least 2 cycles of EP chemotherapy 3 (13)
Disease stage Extensive-stage 22 (96)
Limited-stage 1 (4)
No. of prior anticancer regimens Median 1
Minimum 1
Maximum 3
Best response to prior therapy Partial response 7 (30)
Stable disease 11 (48)
Progressive disease 2 (9)
Unknown 3 (13)